DDInter577 DDInter1082
A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Dobutamine {u} (Compound) resembles {v} (Compound) Masoprocol
Dobutamine {u} (Compound) resembles {v} (Compound) Dopamine
Dobutamine {u} (Compound) binds {v} (Gene) ADRB2
Dobutamine {u} (Compound) downregulates {v} (Gene) DNAJA3
Dobutamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Dobutamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Dobutamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Dobutamine {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Dobutamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Dobutamine (Compound) resembles Masoprocol (Compound)
Dobutamine (Compound) resembles Dopamine (Compound)
Dobutamine (Compound) binds ADRB2 (Gene)
Dobutamine (Compound) downregulates DNAJA3 (Gene)
Dobutamine (Compound) causes Thrombocytopenia (Side Effect)
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Dobutamine may lead to a major life threatening interaction when taken with Cocaine
Dobutamine (Compound) resembles Formoterol (Compound) and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol